Orchid provides a genetic test for determining the health risk of babies, collecting saliva samples from both parents to assess genetic influence on the child's health. Results cover brain health, heart health, cancer, and overall health, with personalized consultations from fertility experts and genetic counselors. Founded in 2019 in Armadale, Australia, the company has raised $16.5M in Series A funding from investors including 23andMe and Day One Ventures. Provider of a genetic test for determining the health risk of babies. The platform collects the saliva sample from both the parents and provides the genetic influence on the child's health. The results are provided for brain health, heart health, cancer, and overall health.
← All startups
Orchid
Series AOrchid provides a genetic test for determining the health risk of babies, collecting saliva samples from both parents to assess genetic influence on the child's health. Results cover brain health, heart health, cancer, and overall health, with personalized consultations from fertility experts and genetic counselors. Founded in 2019 in Armadale, Australia, the company has raised $16.5M in Series A funding from…
About
Business model
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Genetic Diagnosis > Pre-implantation Genetic Diagnosis
Founders & team highlights
Founder with Prior Funding,
Serial Founder
Team background
College Wise > Stanford University
Institutional investors
23andMeDay One VenturesPrometheus FundLIfT BiosciencesRefactor CapitalPebblebedConviction CapitalManaDylan FieldAnne WojcickiFidji SimoBrian ArmstrongElad GilVitalik ButerinAmjad Masad
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.